Supplementary Table 1 from A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Table 1. B7-H3 Expression Patterns for Cancer Cells (CC) and Tumor Vasculature (VAS)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4414101714